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Objectives The aim of this study was to evaluate the long-term safety and durability of efficacy of tadalafil for pulmonary
arterial hypertension.
Background Tadalafil is an oral phosphodiesterase-5 inhibitor approved for PAH treatment. In the multicenter, placebo-
controlled, randomized, 16-week PHIRST (Pulmonary Arterial Hypertension and Response to Tadalafil) study,
tadalafil 40 mg improved exercise capacity and delayed clinical worsening.
Methods Eligible patients from PHIRST received once-daily tadalafil 20 mg (T20 mg) or 40 mg (T40 mg) (n  357) in the
double-blind, 52-week, uncontrolled extension study (PHIRST-2); 293 patients completed PHIRST-2. Durability of
efficacy was explored using the 6-min walk distance (6MWD) test. Clinical worsening and changes in World
Health Organization functional class were evaluated.
Results The safety profile of tadalafil in PHIRST-2 was similar to that in PHIRST, with typical phosphodiesterase-5 inhibitor
adverse events. The 6MWDs achieved in PHIRST for the subset of patients receiving T20 mg and T40 mg in both
PHIRST and PHIRST-2 (406  67 m [n  52] and 413  81 m [n  59] at PHIRST-2 enrollment, respectively) were
maintained at PHIRST-2 completion (415  80 m [n  51] and 410  78 m [n  59], respectively). Numerically
fewer patients who were on T40 mg in PHIRST and PHIRST-2 experienced World Health Organization functional class
deterioration (6% [n  5]) compared with those randomized to T20 mg (9% [n  7]) across both studies. Post hoc
analyses showed that background bosentan use and higher 6MWD at PHIRST baseline were associated with fewer
clinical worsening events.
Conclusions Long-term treatment with tadalafil was well tolerated in patients with pulmonary arterial hypertension. In pa-
tients receiving either T20 mg or T40 mg, the improvements in 6MWD demonstrated in the 16-week PHIRST
study appeared sustained for up to 52 additional weeks of treatment in PHIRST-2. (Pulmonary Arterial Hyperten-
sion and Response to Tadalafil Study; NCT00549302) (J Am Coll Cardiol 2012;60:768–74) © 2012 by the
American College of Cardiology Foundation
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August 21, 2012:768–74 Tadalafil in Pulmonary HypertensionPulmonary arterial hypertension (PAH) is a progressive
disease of the pulmonary circulation leading to early death
(1,2). Regulatory approval of PAH therapies has been
based primarily on improvements in exercise capacity in
short-term, placebo-controlled trials (3). Few studies
have prospectively evaluated the long-term safety and
efficacy of these drugs.
The 16-week, double-blind, placebo-controlled PHIRST
(Pulmonary Arterial Hypertension and Response to Tadala-
fil) study evaluated 4 doses of tadalafil (an oral, once-daily
phosphodiesterase [PDE]-5 inhibitor) and demonstrated that
the highest dose studied, 40 mg, significantly improved 6-min
walk distance (6MWD) versus placebo (p  0.01, pre-
specified alpha value), with a safety profile consistent with its
class (4). Tadalafil 40 mg (T40 mg) significantly improved
time to clinical worsening and quality of life and is the
approved dose for PAH treatment.
Data from the 52-week, double-blind, multicenter, long-
term prospective extension study (PHIRST-2) are now
reported. Because the results of PHIRST were not known
when PHIRST-2 was performed (i.e., whether tadalafil 20
mg [T20 mg] or T40 mg would prove most effective), the
Figure 1 Patient Flow
PAH  pulmonary arterial hypertension; PHIRST  Pulmonary Arterial Hypertensionprimary objective of PHIRST-2
was to evaluate the long-term
safety and durability of efficacy of
both the T20 mg and T40 mg.
Methods
Study design and patient
enrollment. Eligible patients
from PHIRST (4) were enrolled
in PHIRST-2 and assigned to
continue T20 mg (absent clinical
worsening; n  63) or to receive
T40 mg (all other patients; n 
294) once daily for 52 weeks
(Online Fig. 1).
During PHIRST-2, changes in conventional therapies,
such as diuretic agents and digoxin, were allowed. However,
patients were discontinued if they initiated prostacyclin
analogs, PDE-5 inhibitors, and/or an endothelin receptor
antagonist (patients receiving background bosentan at
PHIRST enrollment continued on bosentan in PHIRST-2).
esponse to Tadalafil; T  tadalafil.
Abbreviations
and Acronyms
AE  adverse event(s)
PAH  pulmonary arterial
hypertension
PDE  phosphodiesterase
6MWD  6-min walk
distance
T20 mg  tadalafil 20 mg
T40 mg  tadalafil 40 mg
WHO-FC  World Health
Organization functional classand R
and Re
mg; W
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Tadalafil in Pulmonary Hypertension August 21, 2012:768–74Patients and investigators remained blinded to tadalafil
doses; dose changes were not allowed in PHIRST-2.
The protocol was approved by local institutional review
boards or independent ethics committees, and written
informed consent (or assent when appropriate) was obtained
from all patients.
Outcome measures. Safety was evaluated in PHIRST-2
using adverse events (AEs), physical examinations, electro-
cardiograms, and clinical laboratory data. Treatment-
emergent AEs were defined as events that first occurred or
worsened in intensity after baseline (the run-in period
before randomization in the 16-week PHIRST study).
Durability of efficacy was assessed by 6MWD tests across
PHIRST and PHIRST-2 for all patients entering
PHIRST-2 (n  357). World Health Organization func-
tional class (WHO-FC) and clinical worsening were re-
ported only for patients who entered PHIRST-2 and
received T20 mg or T40 mg in PHIRST (n  161; lower
doses were subtherapeutic in PHIRST and not used in
PHIRST-2). Clinical worsening events were determined by
the local investigator (not adjudicated).
Statistical analysis. Continuous variables are presented as
mean  SD and as numbers of observations. Categorical
variables are summarized as counts and percents. Data for
6MWD were summarized using descriptive statistics and
95% confidence intervals (on the basis of t distribution).
Patients randomized to T20 mg or T40 mg in PHIRST
were included in post hoc subgroup analyses; variables
included change in WHO-FC and clinical worsening from
PHIRST baseline to last observation in PHIRST or
Baseline Characteristics for All Patients Who EnTable 1 Baseline Characteristics for All Pat
Characteristic
T20 mg: T20 mg
(n  63)
Place
(n
Age (yrs) 53 16 5
Female 48 (76%) 60
Race
White 48 (76%) 65
Etiology
Idiopathic/heritable 37 (59%) 49
CTD 16 (25%) 15
ASD 3 (5%) 8
Anorexigen use 4 (6%) 2
Corr-CHD 3 (5%) 1
6MWD (m)* 398 72 36
n 63
WHO-FC* 63
I 5 (8%) 2
II 42 (67%) 31
III 16 (25%) 36
IV 0 (0%) 6
Bosentan use 37 (59%) 41
Values are mean  SD or as n (%). *Reported at PHIRST-2 baseline.
ASD  pulmonary arterial hypertension associated with atrial se
corrective surgical repair of congenital heart disease 1 year before
connective tissue disease; PHIRST Pulmonary Arterial Hypertension
40 mg; T20 mg  tadalafil 20 mg; T2.5–20 mg  tadalafil 2.5 to 20PHIRST-2. Clinical worsening over time and survival wereanalyzed using Kaplan-Meier analysis. Clinical worsening
was defined as death, lung or heart-lung transplantation,
atrial septostomy, receiving any new long-term treatment
for PAH, WHO-FC worsening, or hospitalization for
Figure 2 6-Min Walk Distance for Patients
Who Completed PHIRST-2 (n  293)
Data are presented for PHIRST (16 weeks) and PHIRST-2 (52 weeks). T20 mg
to T20 mg: patients who received tadalafil 20 mg in both studies (n  52).
Placebo to T40 mg: patients who received placebo in PHIRST and switched to
tadalafil 40 mg in PHIRST-2 (n  62). T2.5–10 mg or T20 mg with clinical
worsening to T40 mg: patients who previously received tadalafil 2.5 mg, tadala-
fil 10 mg, or T20 mg (with clinical worsening) in PHIRST and switched to T40
mg in PHIRST-2 (n  120). T40 mg to T40 mg: patients who received T40 mg
in PHIRST and continued to receive T40 mg in PHIRST-2 (n  59). CI  confi-
dence interval.
d PHIRST-2Who Entered PHIRST-2
0 mg
)
T2.5–20 mg: T40 mg
(n  150)
T40 mg: T40 mg
(n  69)
54 15 53 16
) 117 (78%) 53 (77%)
) 122 (81%) 56 (81%)
) 94 (63%) 43 (62%)
) 34 (23%) 13 (19%)
) 10 (7%) 8 (12%)
5 (3%) 4 (6%)
7 (5%) 1 (1%)
0 369 92 403 84
145 69
150 69
5 (3%) 4 (6%)
) 67 (45%) 38 (55%)
) 66 (44%) 27 (39%)
12 (8%) 0 (0%)
) 77 (51%) 37 (54%)
fect; Corr-CHD  pulmonary arterial hypertension associated with
enrollment; CTD  pulmonary arterial hypertension associated with
sponse to Tadalafil; 6MWD 6-min walk distance; T40 mg tadalafil
HO-FC  World Health Organization functional class.tereients
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 75
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August 21, 2012:768–74 Tadalafil in Pulmonary Hypertensionworsening PAH. Time to clinical worsening was defined as
the first day of randomization in PHIRST to the first
occurrence of any clinical worsening event in PHIRST or
PHIRST-2. Patients were discontinued from the study if
they died, underwent lung or heart-lung transplantation, or
started new long-term PAH drugs. Patients were censored
at study completion for any reason other than clinical
worsening. Cox proportional hazards models were per-
formed to identify factors associated with time to clinical
Figure 3 Time to Clinical Worsening
Kaplan-Meier estimates across PHIRST and PHIRST-2 (n  161) for all patients who r
PHIRST. Deterioration of World Health Organization functional class was the most freq
ening (univariate analysis) were pulmonary arterial hypertension duration, baseline 6-m
WHO-FC at PHIRST Baseline and at PHIRST-2Endpoint Across Both PHIRST and the 52-WeekPHIRST-2 Study (n  161) for All Patients WhoReceived T20 mg (n  82) T40 mg (n  79)in PHIRST
Table 2
WHO-FC at PHIRST Baseline and at PHIRST-2
Endpoint Across Both PHIRST and the 52-Week
PHIRST-2 Study (n  161) for All Patients Who
Received T20 mg (n  82) or T40 mg (n  79)
in PHIRST
WHO-FC
T20 mg
(n  82)
T40 mg
(n  79)
Baseline at PHIRST I 0 (0%) 2 (3%)
II 28 (34%) 26 (33%)
III 54 (66%) 51 (65%)
End point at PHIRST-2 (LOCF) Missing 2 (2%) 0 (0%)
I 6 (7%) 7 (9%)
II 43 (52%) 43 (54%)
III 28 (34%) 26 (33%)
IV 3 (4%) 3 (4%)
Change from baseline to week 68 Missing 2 (2%) 0 (0%)
Worsen 7 (9%) 5 (6%)
No change 45 (55%) 47 (59%)
Improved 28 (34%) 27 (34%)
LOCF  last observation carried forward; other abbreviations as in Table 1.worsening events. Univariate and multivariate analysis for
baseline (PHIRST) and post-baseline variables were per-
formed; variables were preselected on the basis of clinical
relevance, and analysis methods were specified before pro-
gramming began.
Results
Of 405 patients treated in PHIRST, the 341 patients who
completed 16 weeks and the 23 patients who discontinued
because of clinical worsening were eligible to enter
PHIRST-2 (4). Of these, 7 declined to enter the extension
(4); thus, 357 patients (88%) entered PHIRST-2 (Fig. 1).
f patients receiving T20 mg (n  82) and T40 mg (n 
9) in PHIRST, 63 and 69 entered PHIRST-2, and 52 and
9 completed PHIRST-2, respectively.
aseline patient characteristics. Table 1 summarizes baseline
emographics for the PHIRST-2 subjects, using data ob-
ained at the end of the PHIRST for 6MWD and
HO-FC baseline. Patients on T20 mg or T40 mg at the
nd of PHIRST had higher 6MWDs and lower WHO-
Cs than those on lower doses or placebo (4). Baseline
emographic characteristics from the PHIRST screening
isit were used for PHIRST-2 demographics.
-min walk distance. For the 111 patients completing
HIRST-2, improvements in 6MWD observed at the end
f PHIRST appeared to be maintained at week 52 of
HIRST-2 (total 68 weeks) (Fig. 2). In contrast, patients
d tadalafil 20 mg (T20 mg) (n  82) or tadalafil 40 mg (T40 mg) (n  79) in
ause of clinical worsening. Factors significantly associated with time to clinical wors-
k distance, bosentan use, and duration of bosentan use at PHIRST baseline.eceive
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Tadalafil in Pulmonary Hypertension August 21, 2012:768–74previously receiving lower doses of tadalafil or placebo in
PHIRST did not improve to similar levels in PHIRST.
WHO-FC. After 68 weeks, for all patients who received T20
mg or T40 mg in PHIRST, 9% and 6% had worsened WHO-
FCs, respectively, while 34% (for both doses) had improved
WHO-FCs compared with PHIRST baseline (Table 2).
Clinical worsening. Across both studies, the incidence of
clinical worsening at week 68 for all patients who
received T20 mg or T40 mg in PHIRST was 27% and
22%, respectively (Fig. 3), with deterioration of WHO-FC the
most frequent cause. Univariate analysis identified PAH
duration (before PHIRST enrollment), baseline 6MWD,
bosentan use, and duration of bosentan use at PHIRST
baseline as factors that were significantly associated with
time to clinical worsening across both studies (Table 3).
Multivariate analysis identified race, PAH etiology, du-
ration of bosentan use, age, baseline WHO-FC, and
6MWD at PHIRST baseline as risk factors for clinical
worsening (Table 3). Patients with connective tissue
disease–associated PAH had 35% clinical worsening at week
68, compared with 24% of patients with idiopathic PAH or
familial PAH and 8% of patients with other etiologies. Of
patients receiving bosentan, 18% had clinical worsening at
week 68 throughout both PHIRST and PHIRST-2, com-
pared with 31% of those not receiving bosentan. Of patients
in PHIRST-2 with baseline 6MWDs 359 m (the median
PHIRST baseline 6MWD), 35% had clinical worsening at
week 68, compared with 14% with baseline 6MWDs 359 m.
Safety. Of the 357 patients who entered and received study
treatment in PHIRST-2, 92% experienced at least 1
treatment-emergent AE by the end of PHIRST-2; 49% of
events were classified by the investigator as possibly related
to the study drug. The most common AE was headache
(Table 4), occurring in 14% to 16% of patients receiving
T20 mg or T40 mg, which was lower than the 32% to 42%
rate seen in PHIRST. Most AEs were mild to moderate in
intensity and did not result in study discontinuation.
Thirty patients (8%) discontinued because of treatment-
emergent AEs, and 91 patients (25.5%) had serious AEs
(including 11 deaths). The majority of serious events were
due to PAH-related conditions.
Deaths and survival. Three deaths occurred in PHIRST
nd 11 in PHIRST-2. Overall survival for all 405 patients
reated in PHIRST was 97% at week 68. Assuming that all
iscontinued patients (n  112) had died (worst case),
overall survival was 72%.
Across PHIRST and PHIRST-2, 3 deaths occurred
among the 82 patients randomized to T20 mg in PHIRST
(including 7 with clinical worsening on T20 mg who
received T40 mg in PHIRST-2). Two deaths occurred
among the 79 patients randomized to T40 mg. Kaplan-
Meier survival estimates at 68 weeks for the T20 mg and
T40 mg doses were 95% (95% confidence interval: 86% to
99%) and 97% (95% confidence interval: 89% to 99%),
respectively (Fig. 4). Assuming that all discontinued pa-
tients died, survival was 66% and 75%, respectively.Discussion
The 52-week PHIRST-2 study is the first to assess long-
term safety and explore long-term efficacy of tadalafil in
PAH; it is also the only study to evaluate the long-term
safety and efficacy of a PDE-5 inhibitor at its approved dose
(5). The long-term extension study of the only other
PDE-5 inhibitor approved for PAH (sildenafil) evaluated a
Univariate and Multivariate Analyses for Baselinea d Pos -B seline Factors Associated WithTime to Clinical Worsening cros PHIRST andPHIRST-2 (n  161)
Table 3
Univariate and Multivariate Analyses for Baseline
and Post-Baseline Factors Associated With
Time to Clinical Worsening Across PHIRST and
PHIRST-2 (n  161)
Variable Hazard Ratio p Value
Univariate analysis
Baseline variables
Age (yrs) 1.014 0.1734
PAH duration (yrs) 0.908 0.0488
Baseline weight (kg) 1.013 0.0937
Baseline 6MWD (m) 0.992 0.0001
Baseline 6MWD (median vs.
median as reference)
0.331 0.0014
Duration of bosentan used (yrs) 0.657 0.0106
Bosentan use (yes vs. no as reference) 0.530 0.0491
WHO-FC (III or IV vs. I or II as reference) 1.121 0.7354
Sex (female vs. male as reference) 0.648 0.1995
PAH etiology 0.0513
Idiopathic Reference Reference
Connective tissue disease vs. idiopathic 1.656 0.1412
Other causes vs. idiopathic 0.290 0.0923
Race 0.3120
W/AI/AN Reference Reference
A vs. W/AI/AN 0.219 0.1348
B/NH/PI vs. W/AI/AN 0.799 0.7117
Post-baseline variables
Dose (continuous) 0.986 0.3635
Dose (T40 mg vs. T20 mg) 0.751 0.3635
End point of 6MWD 0.991 0.0001
Change from baseline to end point in 6MWD 0.993 0.0024
6MWD (time-dependent variable) 0.993 0.0001
Change from baseline in 6MWD
(time-dependent variable)
0.997 0.0712
Multivariate analysis
All baseline and post-baseline variables
Race
W/AI or AN Reference Reference
A vs. W/AI/AN 0.137 0.0496
B/NH/PI vs. W/AI/AN 0.650 0.2379
PAH etiology
Idiopathic Reference Reference
Connective tissue disease vs. idiopathic 2.102 0.0004
Other causes vs. idiopathic 0.512 0.0766
Duration of bosentan used (yrs) 0.709 0.0002
Age (yrs) 0.981 0.0060
WHO-FC (III or IV vs. I or II as reference) 0.597 0.0108
6MWD (time-dependent variable) 0.993 0.0001
A Asian; AI American Indian; AN Alaska Native; B Black or African American; NH Native
awaiian; PAH  pulmonary arterial hypertension; PI  Pacific Islander; W  white; other
bbreviations as in Table 1.dose 4-fold higher than the approved dose (6).
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August 21, 2012:768–74 Tadalafil in Pulmonary HypertensionIn the 16-week PHIRST trial, only T40 mg, the ap-
proved PAH dose, significantly improved exercise capacity,
clinical worsening, and quality of life (4). We now demon-
strate that this dose was generally well tolerated through up
to 68 weeks of dosing, with a safety profile similar to that
previously described through 16 weeks (4). Although cau-
tion must be exercised in interpreting AE rates because of
the absence of a placebo control, the lower incidence of
headache in PHIRST-2 compared with PHIRST among
patients continuing tadalafil suggests that headache associ-
ated with tadalafil waned over time (Table 4).
Important and unique to this study, post hoc univariate and
multivariate analyses found that PHIRST baseline PAH du-
ration and etiology, 6MWD, bosentan use and duration of use,
race, age, and WHO-FC were risk factors for clinical wors-
Most Frequent TEAEs Occurring in >10% of Patients Who EnteredTable 4 Most Frequent TEAEs Occurring in >10% of Patients W
TEAE
T20 mg: T20 mg
(n  63)
Placebo: T4
(n  75
Headache 9 (14%) 21 (28%
Diarrhea 7 (11%) 7 (9%)
Back pain 3 (5%) 12 (16%
Peripheral edema 6 (10%) 7 (9%)
Upper respiratory tract infection 7 (11%) 9 (12%
Dizziness 4 (6%) 9 (12%
Palpitations 5 (8%) 5 (7%)
Nasopharyngitis 5 (8%) 10 (13%
Dyspnea 5 (8%) 6 (8%)
TEAE  treatment-emergent adverse event; other abbreviations as in Table 1.
Figure 4 Survival Across Both PHIRST and PHIRST-2 (N  161
Who Received T20-mg (n  82) or T40-mg (n  79) i
Kaplan-Meier estimated survival across both PHIRST and PHIRST-2 (n  161) for
(n  79) in PHIRST. Of the 161 patients who received either T20-mg or T40-mg in
68 weeks were 95% for T20-mg and 97% for T40-mg.ening. These observations are critical in interpreting the findings
from this and other trials and call for a need to reevaluate trial
design when add-on therapy is being assessed (7,8).
Two additional characteristics in this study were unique.
First, unlike other long-term studies, the addition of PAH-
specific therapy other than bosentan was not permitted in
PHIRST-2 (54% of patients in PHIRST-2 were receiving
background bosentan at PHIRST enrollment). Despite this,
the 161 patients on T20 mg and T40 mg in PHIRST-2 had
estimated survival of 95% and 97%, respectively, which is
comparable with estimates from other long-term studies in
which additional PAH drugs were allowed (9–12). These
results must be exercised with caution, because survival
status was not available for patients who discontinued
PHIRST or PHIRST-2 for other reasons (n  22).
ST-2ntered PHIRST-2
T2.5–20 mg: T40 mg
(n  150)
T40 mg: T40 mg
(n  69)
Total
(n  357)
38 (25%) 11 (16%) 79 (22%)
21 (14%) 11 (16%) 46 (13%)
19 (13%) 7 (10%) 41 (12%)
22 (15%) 6 (9%) 41 (12%)
15 (10%) 10 (15%) 41 (12%)
24 (16%) 3 (4%) 40 (11%)
21 (14%) 7 (10%) 38 (11%)
13 (9%) 9 (13%) 37 (10%)
15 (10%) 10 (15%) 36 (10%)
All Patients
IRST
ients who received tadalafil 20 mg (T20-mg) (n  82) or tadalafil 40 mg (T40-mg)
T, 5 patients died across both PHIRST and PHIRST-2. Survival estimates atPHIRho E
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)
)
)
)
)
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Tadalafil in Pulmonary Hypertension August 21, 2012:768–74Second, patients who were initially randomized to pla-
cebo, tadalafil 2.5 mg, or tadalafil 10 mg (or T20 mg with
clinical worsening) in PHIRST had lower 6MWDs
throughout PHIRST-2 than patients taking randomized
T20 mg or T40 mg, consistent with the hypothesis that a
delay in the initiation of an effective drug or dose may result
in less long-term efficacy.
Study limitations. Without a placebo control, these results
should be interpreted with caution. Nevertheless, the long-
term efficacy data suggest an acceptable safety profile for
tadalafil at these doses. Also, given the progressive nature of
PAH, the fact that 6MWDs remained improved in
PHIRST-2 compared to PHIRST baseline suggests that
tadalafil provided long-term maintenance of exercise capacity.
Not all eligible patients entered this extension study.
Patients who received T40 mg in PHIRST and had clinical
worsening were not allowed to enter PHIRST-2. Further-
more, survival outcome data were not available for patients
who prematurely discontinued PHIRST or PHIRST-2.
Finally, extrapolation of trial results to community practice
should be undertaken with caution.
Conclusions
These data demonstrate that the long-term safety profile of
tadalafil appears similar to that in the 16-week PHIRST
study and that treatment for up to 68 weeks appears safe and
well tolerated. For patients receiving T20 mg and T40 mg,
the short-term improvements in exercise capacity observed
in PHIRST appeared to be maintained for an additional 52
weeks in PHIRST-2.
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